摘要
目的通过观察二甲双胍(MET)与罗格列酮(RSG)两种药物联用对2型糖尿病(T2DM)患者炎性反应因子白细胞介素-6(IL-6)、血糖及血脂表达的影响,探讨两种药物联用的临床意义。方法以仅服用MET的T2DM患者为对照组,40例;联合服用MET及RSG组为实验组,45例,疗程为3个月。分别测定受试者治疗前后空腹血清IL-6、血糖及血脂。结果与治疗前相比,各组患者空腹血清IL-6、血糖及血脂水平均明显降低,但实验组降低更明显,且实验组IL-6与对照组相比差异有统计学意义(P<0.05)。结论联合应用MET与RSG可以明显降低T2DM患者的血清IL-6、空腹血糖、血脂水平,比独立应用MET更为有效。
Objective To study the clinical significance of coadministered metformin and rosiglitazone by ob serving the effects of the two medicine on IL6, blood glucose and blood lipid in type Ⅱ diabetes mellitus patients （T2DM）. Methods Put 40 cases who only took MET into the control group and 45 cases who took coadministered MET and RSG into the experimental group. The course of treatment for both the two groups is 3 months. The fast serum IL,fast blood glucose（FBG ） and fast blood lipid were determined before and after the treatment. Results The levle of IL -6, FBG and blood lipid are all lower than those before the treatment in the two groups, but the effects in the experimefital group are more .significant than those in the control group,and the IL -6 in the experimental group is decreased significantly compared with the control group（P〈0.05）. Conclusion The efficacy of coadministered metformin and rosiglitazone is better than that of those who noly took metformin on decreasing IL-6, FBG and blood lipid in T2DM.
出处
《检验医学与临床》
CAS
2010年第10期915-916,共2页
Laboratory Medicine and Clinic
